Braun OEM Division
If you need a trusted outsourcing partner for pharmaceutical contract manufacturing and customized medical devices, turn to B. Braun OEM - one of the world?s leading healthcare companies.
B. Braun OEM Division
Customized Kits – from concept to customization.
As one of the leading companies in the healthcare market, B. Braun is your professional and reliable outsourcing partner for pharmaceutical contract manufacturing and customized medical devices. Our product line has everything for safe and exact infusion therapy.
Based on our extensive product portfolio, long lasting experiences and our complete project management capabilities we are your ideal partner to provide you with standard products or products with modified characteristics assembled in customized kits. Based on your drug we can offer you all disposable items which are required for a certain procedure. You can use your possibility to combine different products or to pair one of our products with one of yours. Your possibilities are nearly endless. We also cover registration issues on the basis of your indications (e.g. labeling, instructions for use, documents, registration).
Visit our booth no. 42F29 at the ICSE in Frankfurt and learn more about how we design, combine and produce customized kits for dozens of applications. We accompany you from your first idea to your individual kit.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
